Time from melanoma diagnosis to surgery is commonly delayed in Medicare patients
the ONA take:
Surgery is delayed in 1 in 5 Medicare patients with melanoma, according to a Yale study. Melanoma is the leading cause of new cancer diagnoses in the United States.
In this population-based analysis of delay of surgery among Medicare patients with melanoma, culled from the Surveillance, Epidemiology, and End Result-Medicare database, the researchers reviewed more than 32,000 cases of melanoma diagnosis in Medicare patients.
No gold standard exists on time from diagnosis to study; however, the recommended timeframe from between diagnosis and surgery is less than 6 weeks.
This study found that 22% of patients waited longer than 1.5 months for surgery, and surgery was delayed more than 3 months in 8% of patients. Delays were most common when the treating clinician was not a dermatologist (eg, a primary care physician or general surgeon).
In addition, study findings revealed a significant difference in timing from melanoma diagnosis to surgery for Medicare patients.
The researchers suggest further studies should seek to identify reasons for the delay to surgery and to consider how coordination between care providers can be improved.
Surgery is delayed in 1 in 5 Medicare patients with melanoma.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|